Staten Island University Hospital Prince’s Bay awardedPrimary Stroke Certification from The Joint Commission

Staten Island University Hospital (SIUH) Prince’s Bay has earned The Joint Commission’s Gold Seal of Approval® and the American Stroke Association’s Heart-Check mark for Primary Stroke Certification.
SIUH Prince’s Bay underwent a rigorous onsite review in August.  During the visit, a team of Joint Commission reviewers evaluated compliance with related certification standards including the use of evidence-based guidelines for stroke care, adoption of standardized performance measures, composition of the program’s interdisciplinary team, program’s mission and scope of services, stroke policies, EMS protocols, and imaging capabilities.
Joint Commission standards are developed in consultation with health care experts and providers, measurement experts and patients. The reviewers also conducted onsite observations and interviews.
“Primary Stroke Certification recognizes health care organizations committed to fostering continuous quality improvement in patient safety and quality of care,” says Mark Pelletier, RN, MS, chief operating officer, Accreditation and Certification Operations, and chief nursing executive, The Joint Commission. “We commend SIUH Princes’ Bay for using certification to reduce variation in its clinical processes and to strengthen its program structure and management framework for stroke patients.”
“We congratulate SIUH Prince’s Bay for this outstanding achievement,” says Nancy Brown, chief executive officer, the American Stroke Association. “This certification reflects its commitment to providing the highest quality of care for stroke patients.”
“SIUH Prince’s Bay has been the main hospital for the South Shore of Staten Island for many years,” said Yasir El-Sherif, director of the Stroke Services at SIUH. “Now with the Joint Commission certification we will be able to provide top quality care in Stroke to the residents of Staten Island. Our multidisciplinary team is composed of a rather large number of Staten Islanders who are dedicated to helping elevate Neuroscience care to their family, friends and fellow Staten Islanders by constantly driving safety, quality, and compassionate care.”
SIUH’s journey towards the Primary Stroke Certification ramped up two years ago with the creation of a core group and framework led by their stroke program. This team, comprised of multidisciplinary clinical providers and administrative leaders, focused on certification standards, clinical practice guidelines, process improvements, performance measures, and outcomes all while establishing a consistent approach to stroke care.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.